EP Patent

EP3260455A1 — Selective pi3k delta inhibitors

Assigned to Rhizen Pharmaceuticals AG · Expires 2017-12-27 · 8y expired

What this patent protects

The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

USPTO Abstract

The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

Drugs covered by this patent

Patent Metadata

Patent number
EP3260455A1
Jurisdiction
EP
Classification
—
Expires
2017-12-27
Drug substance claim
No
Drug product claim
No
Assignee
Rhizen Pharmaceuticals AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.